Department of Clinical Biochemistry, Medical School, University of Athens, Attikon General University Hospital, 1 Rimini Street, Chaidari, 12462 Athens, Greece.
Biomark Med. 2014;8(1):107-18. doi: 10.2217/bmm.13.99.
Excess body weight is associated with various types of malignancies. Resistin, originally described as an adipocyte-specific hormone modulating insulin resistance in rodents, may exhibit proliferative, antiapoptotic, proinflammatory, proangiogenic and metastatic properties. Accumulating evidence supports a role of resistin as a risk factor and potential diagnostic and prognostic biomarker in cancer. In this report, the current knowledge about resistin's properties and pathophysiological implications in cancer in the context of dysregulated adipose tissue in obesity is summarized; clinical translations, preventive and therapeutic considerations, and future perspectives in the field of resistin research are discussed. At the same time, several enigmatic issues involving resistin receptor and signaling pathways remain to be clarified in order to unmask its ontological role in cancer pathophysiology.
超重与多种类型的恶性肿瘤有关。抵抗素最初被描述为一种脂肪细胞特异性激素，可调节啮齿动物的胰岛素抵抗，它可能具有增殖、抗凋亡、促炎、促血管生成和转移的特性。越来越多的证据支持抵抗素作为癌症的危险因素和潜在的诊断及预后生物标志物。本报告总结了肥胖症中失调的脂肪组织背景下抵抗素在癌症中的特性和病理生理学意义的最新知识；讨论了抵抗素研究领域的临床转化、预防和治疗方面的考虑因素以及未来展望。同时，为了揭示抵抗素在癌症病理生理学中的本体作用，仍有几个涉及抵抗素受体和信号通路的神秘问题需要澄清。
